Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population

• Status: Completed
• Trial end date: 2005-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose is to demonstrate the utility of Caduet (amlodipine/atorvastatin) in the African American population

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Amlodipine; Amlodipine, atorvastatin drug combination; Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• African American men and women with concurrent hypertension and dyslipidemia that is either treated or untreated

• Subjects must satisfy the blood pressure and LDL-C inclusion criteria for their respective Cardiovascular Risk group determined at screening

Exclusion Criteria:

• Subjects currently being treated with concomitant amlodipine and atorvastatin therapy, including Caduet

• Subjects with blood pressure at goal